The role of renin-angiotensin-aldosterone system inhibition in chronic kidney disease.

摘要: Chronic kidney disease (CKD) is emerging as a new health pandemic. Underlying the global rise in CKD an increase diabetes, hypertension and other cardiovascular risk factors leading to progressive renal dysfunction. Emerging evidence strongly suggests that achieving target blood pressure goals via inhibition of renin–angiotensin–aldosterone system confers significant cardioprotection for patients with CKD. Angiotensin-converting enzyme inhibitors (ACEIs) angiotensin receptor blockers (ARBs) lower pressure, reduce proteinuria both progression adverse events. The role aldosterone combination therapy, such ACEI/ARB, are under investigation. As our understanding basic mechanisms underlying advances, novel therapies targeting post-translational endothelial mesangial messengers downstream from II may become available clinical use.